Erbitux - Merck KGaA/Bristol-Myers Squibb

Cost: $137,953 per U.S. patient per year

Nowadays, Erbitux isn't just a cancer drug, which are often pricey in general. It's a targeted cancer drug. Back in 2009, the FDA allowed Merck ($MRK) to narrow Erbitux's indication for advanced colon cancer, changing the label to recommend the drug for treatment of EGFR-expressing tumors only in patients without a mutation in the KRAS gene.

The move may have narrowed Erbitux's patient pool, but the German pharma has said it thinks better efficacy data in a smaller group can help marketing teams stress the med's benefits. Analysts, though, don't appear sold; they expect the med's peak sales to hit $1.25 billion for Merck this year before slipping to $1.1 billion by 2018.

That's not such great news for Merck, for which Erbitux is a No. 2 seller. Its prescription drug business, Serono, is already struggling after not delivering a major new drug since 2013. Right now, though, the drug is on the rise, with sales expanding 5.9% in 2013.

For more:
Special Report: Top 10 best-selling cancer drugs of 2013 - Erbitux
Merck KGaA eyes KRAS-gene focus to boost Erbitux sales
Merck yanks European app for Erbitux in lung cancer
BMS, Lilly's targeted drug Erbitux gets new FDA nod

-- Carly Helfand (email | Twitter)

Erbitux - Merck KGaA/Bristol-Myers Squibb
Read more on

Suggested Articles

FDA officials say Novartis took too long to launch a formal probe into allegations of Zolgensma data manipulation.

Should Johnson & Johnson owe billions to fix Oklahoma's opioid crisis? After weeks of trial testimony, a judge will have his say Monday afternoon.

After Endo and Allergan agreed to settle with two Ohio counties on opioid charges this week, the state’s AG has a message: You’re not off the hook.